Thirty-two companies raised $1.6 billion in follow-ons in 3Q13. That is up from the $1.3 billion raised in 3Q12 but below the $2.3 billion in 1Q13 and $4.2 billion in 2Q13. The 3Q13 group of follow-ons is up a median of 12%, led by Cancer Genetics Inc. (NASDAQ:CGIX), whose market cap has doubled since the DNA-based cancer diagnostics company's August deal. In April, the company completed an IPO for $6.9 million.

Most recent deal at top. (A) Follow-ons of units consisting of stock and warrants are excluded from the post-money and percentage change